Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported an 80.29% year-on-year (YoY) rise in net profit after tax for the fiscal year (FY) of 2024/2025, according to the company’s financial statements filed to the Egyptian Exchange (EGX) on September 18th.

Kahira Pharmaceuticals and Chemical Industries Company (CPCI) unveiled cash dividends distribution of EGP 12.83 per share for the fiscal year (FY) 2023/2024.

Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported a 153.5% year-on-year (YoY) rise in net profit after tax for the fiscal year (FY) of 2023/2024.

Kahira Pharmaceutical’s net profits after tax climbed 248% year on year (YoY) for the first nine months of fiscal year (FY) 2023/2024, hitting EGP 195.072 million.

Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported a 140.7% year-on-year leap in net profit after tax for the first half (H1) of the fiscal year (FY) 2023/2024, according to the company’s unaudited financial indicators filed to the Egyptian Exchange (EGX).

Kahira Pharmaceuticals and Chemical Industries Company (CPCI) has announced the distribution of cash dividends of EGP 5 per share for the fiscal year (FY) 2022/2023 on December 10th, according to the company’s financial statement filed to the Egyptian Exchange (EGX) on December 5th.

Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported a 52.5% year-on-year (YoY) increase in net profits after tax for the first quarter of fiscal year (FY) 2023/2024.

Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported a 41.42% year-on-year (YoY) decline in net profit after tax for fiscal year (FY) 2022/2023.

Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products for human and veterinary use.